Ulrich Bogdahn

Bio: Ulrich Bogdahn is an academic researcher from University of Regensburg. The author has contributed to research in topics: Neural stem cell & Neurogenesis. The author has an hindex of 67, co-authored 344 publications receiving 32279 citations. Previous affiliations of Ulrich Bogdahn include Hoffmann-La Roche & Volkswagen Foundation.

Indikationen und Outcome beatmeter Patienten einer neurologischen Intensivstation

Abstract: In dieser Studie charakterisierten wir die beatmeten Patienten einer neurologischen Intensivstation (NITS) im Zeitraum 2006 bis 2008 in einer rein neurologischen Klink in einer sog. „Stand-alone-Situation. Zudem untersuchten wir die Langzeitprognose und Lebensqualitat der Uberlebenden. Diese retrospektive Studie umfasst alle beatmeten Patienten von 10/2006 bis 12/2008 einer neurologischen Intensivstation, analysiert mit prospektiv definierten Kriterien anhand der Aktenlage den Intensivaufenthalt und erfasst die aktuelle Lebensqualitat. Wir ermittelten unter anderem die endgultigen Diagnosen, Dauer der Intensivpflichtigkeit und Beatmungsdauer sowie den jeweils hochsten SAPS-II-Score und die Komplikationen wahrend des Aufenthaltes. Anhand der Diagnosen wurden die Patienten in Gruppen eingeteilt: vaskular, entzundlich, neurodegenerativ, hereditar, epileptisch und sonstige. Zusatzlich wurden die Patienten kontaktiert und per Fragebogen der Barthel-Index (BI) sowie die Werte auf der modifizierten Rankin-Skala (mRS) ermittelt. Insgesamt wurden im beobachteten Zeitraum 201 von 512 Patienten auf der NITS beatmet. Vaskulare Erkrankungen waren fuhrende Ursache fur die Therapie auf der Intensivstation (47,8%), gefolgt von entzundlichen Erkrankungen (22,8%) und Epilepsien (13%). Die Dauer der Beatmung betrug median 9 Tage bei einer mittleren Behandlungsdauer von 16 Tagen (Range 1–57). Bereits wahrend des Aufenthaltes verstarben 31 Patienten (entsprechen15,4% aller Behandelten). Weitere 32 der 170 uberlebenden Patienten (entsprechen 18,8% der entlassenen Patienten) verstarben im Median von 2 Monaten nach Entlassung. Outcomedaten konnten anhand von 67 von 170 versandten Fragebogen und 86 Rehabilitationsabschlussberichten erhoben werden, sodass letztendlich Nachuntersuchungsdaten von insgesamt 121 Patienten der 170 uberlebenden beatmeten Intensivpatienten vorlagen. Davon gaben 42,2% keine bzw. leichte Beeintrachtigungen/Pflegebedurftigkeit im Alltag, allerdings auch 38,0% schwere Beeintrachtigungen/dauerhafte Pflegebedurftigkeit laut BI an. Die Auswertung der mRS ergab, dass immerhin noch 49,6% der 170 nachuntersuchten Patienten subjektiv eine schwere Restsymptomatik aufweisen. Das impliziert, dass vorhandene Residuale nicht zwangslaufig zu einer entsprechenden Pflegebedurftigkeit fuhren. Mehr als ein Drittel der Patienten der hier analysierten NITS wurden beatmungspflichtig, wobei der Schwerpunkt bei den vaskularen Erkrankungen liegt und somit die Uberschneidung zwischen Stroke-Unit und Intensivstation verdeutlicht. Trotz langer Beatmungs- und Intensivdauer zeigt mehr als ein Drittel der uberlebenden Patienten nur leichte oder gar keine Beeintrachtigungen bei Aktivitaten des taglichen Lebens, wobei doch scheinbar ein Teil der Patienten trotzdem subjektiv unter einer nicht unerheblichen Restsymptomatik leidet. Ein weiteres Drittel uberlebte mit schweren Einschrankungen bis hin zur kompletten Pflegebedurftigkeit. Die Daten unterscheiden sich bez. den wenigen Publikationen uber NITS trotz der besonderen Stand-alone-Situation kaum. Der Case-Mix-Index betrug im Mittel 0,3/Tag und zeigt die wirtschaftliche Bedeutung im Vergleich zu anderen neurologischen Behandlungsformen an.

Deuterium-containing pharmaceutical compositions for destroying tumors

Abstract: The invention pertains to the use of a pharmaceutical composition containing deuterium and/or deuterated substances and/or substances that enrich or release deuterium to selectively destroy tumor cells and/or tumor metastases or to prevent metastasizing and/or local recurrence of tumors as well as their regrowth.

Complete response after treatment with a somatostatin analogue in an adult patient with recurrent medulloblastoma

Abstract: Department of Neurology, University of Regensburg, Regensburg, Germany, Clinical Neurooncology Unit, Department of Neurology, University of Bonn, Bonn, Germany, Department of Hematology and Oncology, Internal Medicine, University of Regensburg, Regensburg, Germany, Department of Nuclear Medicine, University of Regensburg, Regensburg, Germany, and Department of Internal Medicine I, University of Bonn, Germany

Targeted downregulation of TGF-beta2 as immunotherapy for high-grade glioma: A phase IIb study

Abstract: 1537 Background: High-grade (malignant) glioma are highly aggressive tumors showing marked overexpression of transforming growth factor-beta2 (TGF-beta2). TGF-beta plays a key role in malignant pro...

Guidelines for the Early Management of Patients With Acute Ischemic Stroke A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association

Abstract: Background and Purpose—The authors present an overview of the current evidence and management recommendations for evaluation and treatment of adults with acute ischemic stroke. The intended audienc...

Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition

Abstract: The 3rd edition of the International Classification of Headache Disorders (ICHD-3) may be reproduced freely for scientific, educational or clinical uses by institutions, societies or individuals. Otherwise, copyright belongs exclusively to the International Headache Society. Reproduction of any part or parts in any manner for commercial uses requires the Society’s permission, which will be granted on payment of a fee. Please contact the publisher at the address below. International Headache Society 2013–2018. Applications for copyright permissions should be submitted to Sage Publications Ltd, 1 Oliver’s Yard, 55 City Road, London EC1Y 1SP, United Kingdom (tel: þ44 (0) 207 324 8500; fax: þ44 (0) 207 324 8600; permissions@sagepub.co.uk) (www.uk.sagepub.com). Translations

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

Abstract: BACKGROUND: In 2004, a randomised phase III trial by the European Organisation for Research and Treatment of Cancer (EORTC) and National Cancer Institute of Canada Clinical Trials Group (NCIC) reported improved median and 2-year survival for patients with glioblastoma treated with concomitant and adjuvant temozolomide and radiotherapy. We report the final results with a median follow-up of more than 5 years. METHODS: Adult patients with newly diagnosed glioblastoma were randomly assigned to receive either standard radiotherapy or identical radiotherapy with concomitant temozolomide followed by up to six cycles of adjuvant temozolomide. The methylation status of the methyl-guanine methyl transferase gene, MGMT, was determined retrospectively from the tumour tissue of 206 patients. The primary endpoint was overall survival. Analyses were by intention to treat. This trial is registered with Clinicaltrials.gov, number NCT00006353. FINDINGS: Between Aug 17, 2000, and March 22, 2002, 573 patients were assigned to treatment. 278 (97%) of 286 patients in the radiotherapy alone group and 254 (89%) of 287 in the combined-treatment group died during 5 years of follow-up. Overall survival was 27.2% (95% CI 22.2-32.5) at 2 years, 16.0% (12.0-20.6) at 3 years, 12.1% (8.5-16.4) at 4 years, and 9.8% (6.4-14.0) at 5 years with temozolomide, versus 10.9% (7.6-14.8), 4.4% (2.4-7.2), 3.0% (1.4-5.7), and 1.9% (0.6-4.4) with radiotherapy alone (hazard ratio 0.6, 95% CI 0.5-0.7; p<0.0001). A benefit of combined therapy was recorded in all clinical prognostic subgroups, including patients aged 60-70 years. Methylation of the MGMT promoter was the strongest predictor for outcome and benefit from temozolomide chemotherapy. INTERPRETATION: Benefits of adjuvant temozolomide with radiotherapy lasted throughout 5 years of follow-up. A few patients in favourable prognostic categories survive longer than 5 years. MGMT methylation status identifies patients most likely to benefit from the addition of temozolomide. FUNDING: EORTC, NCIC, Nelia and Amadeo Barletta Foundation, Schering-Plough.

MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma

Abstract: background Epigenetic silencing of the MGMT (O 6 -methylguanine–DNA methyltransferase) DNArepair gene by promoter methylation compromises DNA repair and has been associated with longer survival in patients with glioblastoma who receive alkylating agents. methods We tested the relationship between MGMT silencing in the tumor and the survival of patients who were enrolled in a randomized trial comparing radiotherapy alone with radiotherapy combined with concomitant and adjuvant treatment with temozolomide. The methylation status of the MGMT promoter was determined by methylation-specific polymerase-chain-reaction analysis. results The MGMT promoter was methylated in 45 percent of 206 assessable cases. Irrespective of treatment, MGMT promoter methylation was an independent favorable prognostic factor (P<0.001 by the log-rank test; hazard ratio, 0.45; 95 percent confidence interval, 0.32 to 0.61). Among patients whose tumor contained a methylated MGMT promoter, a survival benefit was observed in patients treated with temozolomide and radiotherapy; their median survival was 21.7 months (95 percent confidence interval, 17.4 to 30.4), as compared with 15.3 months (95 percent confidence interval, 13.0 to 20.9) among those who were assigned to only radiotherapy (P=0.007 by the log-rank test). In the absence of methylation of the MGMT promoter, there was a smaller and statistically insignificant difference in survival between the treatment groups. conclusions Patients with glioblastoma containing a methylated MGMT promoter benefited from temozolomide, whereas those who did not have a methylated MGMT promoter did not have such a benefit.